Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of WSD0922-FU in EGFR C797S-mutant advanced or metastatic lung adenocarcinoma after progression on first-line osimertinib
CTR20252651Phase 2Active
- Sponsor
- Versantus
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of WSD-0922 in Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by Versantus. Started Aug 2025; status: active.
02
Drugs
WSD-0922
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on CTR20252651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252651.